Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network

Javier de la Rubia, Roman Hajek, Jiri Minarik et al. Nov 03, 2025 pp. 2803-2803 10.1182/blood-2025-2803

Abstract Introduction: Understanding the real-world evolution in the multiple myeloma (MM) pathway enhances evidence-based treatment decisio...

A US retrospective observational Study of rituximab initial and retreatment in patients with warm autoimmune hemolytic anemia (wAIHA)

Daniel Labson, Irina Murakhovskaya, Alexander Litvintchouk et al. Nov 03, 2025 pp. 6249-6249 10.1182/blood-2025-6249

Abstract BackgroundWarm autoimmune hemolytic anemia (wAIHA) is the most prevalent type (60-70%) of autoimmune hemolytic anemia (AIHA) and is...

BCL-2 inhibition in North American adult T-cell leukemia/lymphoma: Preclinical insights and early clinical outcomes

Ankit Tanwar, Emma Cordover, Salman Sadullah Usmani et al. Nov 03, 2025 pp. 3304-3304 10.1182/blood-2025-3304

Abstract Background: North AmericanAdult T-cell leukemia/lymphoma (NA ATLL) is an aggressive malignancy of mature CD4⁺ T cells associated wit...

Stratos: An AI-driven biomarker signature for prognostic risk stratification in transplant-associated thrombotic microangiopathy - a nationwide, multicenter study

Zhuo-Yu An, Liping Dou, Yun He et al. Nov 03, 2025 pp. 120-120 10.1182/blood-2025-120

Abstract Introduction Transplant-associated thrombotic microangiopathy (TA-TMA) represents a critical complication in hematopoietic stem cel...

Bayesian machine learning, medical history, and predictive models for early diagnosis of systemic light chain amyloidosis

Anita D'Souza, Liliana Pezzin, Noel Estrada-Merly et al. Nov 03, 2025 pp. 3967-3967 10.1182/blood-2025-3967

Abstract Introduction Early diagnosis of light chain amyloidosis (AL) is critical to prevent irreversible organ damage and improve survival....

Efficacy and safety of bruton tyrosine kinase (BTK) inhibitor zanubrutinib in relapsed/refractory warm autoimmune hemolytic anemia (wAIHA) after multiple lines of therapy: A prospective phase 2 single-arm study

Miao Chen, Ziwei Liu, Chen Yang et al. Nov 03, 2025 pp. 1104-1104 10.1182/blood-2025-1104

Abstract Objective: To evaluate the efficacy and safety of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib in patients with relapsed...

Rituximab versus watchful waiting for asymptomatic advanced stage low tumor burden follicular lymphoma: A systematic review and meta-analysis

Hosana Candreva, Mehak Dang, Yujin Jeong et al. Nov 03, 2025 pp. 7126-7126 10.1182/blood-2025-7126

Abstract Introduction The optimal initial management of asymptomatic patients with advanced-stage, low tumor burden foll...

Multi-omics integration reveals therapeutic vulnerabilities and immune microenvironment subtypes in Acute Myeloid Leukemia

Elina Alaterre, Hugues De Boussac, Alboukadel Kassambara et al. Nov 03, 2025 pp. 1715-1715 10.1182/blood-2025-1715

Abstract Background: Acute myeloid leukemia (AML) is a complex disease marked by a multitude of genetic mutations and dysregulated gene expr...

Double burden: Bleeding disorders and their impact on cardiovascular mortality across demographics and geography in the United States, 1999–2020

Hardik Jain, Mandeepsinh Vashi, Khushbu Patel et al. Nov 03, 2025 pp. 4867-4867 10.1182/blood-2025-4867

Abstract Background: Bleeding disorders, though classically linked to hemorrhagic complications, also influence cardiova...

Home monitoring of neutrophil counts by patients with cyclic and congenital neutropenia

David Dale, Audrey Anna Bolyard, Merideth Kelley et al. Nov 03, 2025 pp. 1207-1207 10.1182/blood-2025-1207

Abstract Background: Currently most blood cell counts are performed at clinical laboratories which is time-consuming, costly and may expose...

Optimizing fludarabine exposure using pharmacokinetic modeling in pediatric patients receiving tisagenlecleucel: A step toward personalized lymphodepletion

Susie Long, Veronika Bachanova, Qing Cao et al. Nov 03, 2025 pp. 2375-2375 10.1182/blood-2025-2375

Abstract Introduction Tisagenlecleucel (tisa-cel), a CD19-directed CAR T-cell therapy, has transformed therapy in relapsed/refractory pediat...

Signal-rich and signal-poor: Divergent detection of early bacterial sepsis and latent viral complications after hematopoietic stem cell transplantation in the FDA adverse event reporting system

Manzer Ali, Bolivia Fernandes, Rajesh Thirumaran et al. Nov 03, 2025 pp. 2509-2509 10.1182/blood-2025-2509

Abstract Background Bacterial sepsis, cytomegalovirus (CMV) reactivation, Epstein–Barr virus post-transplant lymphoproli...

Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia

Melissa Kinney, Bevin Noone, Theresa Chera et al. Nov 03, 2025 pp. 948-948 10.1182/blood-2025-948

Abstract Introduction: The commercial delivery of gene therapy for hemoglobinopathies requires not only scientific rigor but also system-lev...

Pomalidomide salvage in T-cell engager monotherapy failures: Real-world experience with talquetamab or elranatamab with pomalidomide combinations in heavily pretreated multiple myeloma

James Di Palma-Grisi, David Siegel, Noa Biran et al. Nov 03, 2025 pp. 2229-2229 10.1182/blood-2025-2229

Abstract Background: T-cell engager (TCE) therapies (talquetamab [anti-GPRC5D] and elranatamab [anti-BCMA]) demonstrate proven efficacy in h...

Understanding the impact of chronic red blood cell transfusion on day-to-day functioning in sickle cell disease (SCD): A mixed methods study of pediatric and adult experience

Chinonso Onuoha, Paul Mihas, Marcella Boynton et al. Nov 03, 2025 pp. 2949-2949 10.1182/blood-2025-2949

Abstract Background Chronic red blood cell transfusion (CRCT) is a therapeutic cornerstone for individuals with sickle cell disease (SCD), c...

Additional genetic targets are present in the majority of AML patients with NPM1, KMT2A or NUP98 aberrations potentially impacting combination therapy with menin inhibitors

Rainer Ordemann, Sandra Huber, Alessandro Baldi et al. Nov 03, 2025 pp. 5248-5248 10.1182/blood-2025-5248

Abstract Introduction: The exploration of menin inhibitors has opened new ways for targeted treatment – however, it is s...

Real-world treatment patterns, patient characteristics, and outcomes of cbtki-based therapies amongst a contemporary cohort of patients with R/R MCL in the United States

Kami Maddocks, Marsha Tracey, Katherine Winfree et al. Nov 03, 2025 pp. 2725-2725 10.1182/blood-2025-2725

Abstract Background: Patients (pts) with mantle cell lymphoma (MCL) frequently require initiation of treatment (tx) at diagnosis. While firs...

Murine reticulated platelets generated during recovery from antibody-induced thrombocytopenia are functionally impaired and transcriptionally rewired

Muataz Ali Hamad, Nancy Schanze, Krystin Krauel et al. Nov 03, 2025 pp. 3015-3015 10.1182/blood-2025-3015

Abstract Reticulated platelets (RP) are newly released, RNA-rich platelets that often increase during recovery from thrombocytopenia. Though...

First report of real-word outcomes of chronic myeloid leukemia in Uruguay in tyrosine kinase inhibitor era

Virginia Bove, Mariana Lorenzo, Isabel Moro et al. Nov 03, 2025 pp. 7296-7296 10.1182/blood-2025-7296

Abstract Introduction Several reports on chronic myeloid leukemia (CML) real-world outcomes have been published, although limited data is av...

Plasma protein ADAMTS8 as a minimally invasive favorable prognostic biomarker in mantle cell lymphoma

Ingrid Glimelius, Tove Selvin, Mattias Berglund et al. Nov 03, 2025 pp. 3576-3576 10.1182/blood-2025-3576

Abstract Introduction Mantle cell lymphoma (MCL) is characterized by biological and clinical heterogeneity ranging from an indolent to highly...

ALIDHE: An ongoing open-label phase 3b study investigating ivosidenib with azacitidine in clinical practice in adult patients with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (IC)

Paresh Vyas, Christian Récher, Hartmut Döhner et al. Nov 03, 2025 pp. 3443-3443 10.1182/blood-2025-3443

Abstract Introduction Mutations in IDH1 occur in 6–10% of patients (pts) with AML. Ivosidenib (IVO), an oral, targeted, small-molecule inhibi...

UCD19 CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia in first complete remission with MRD positivity: Preliminary Results of A phase I/ib clincal trial

Marc Schwartz, Navin Pinto, Michael Verneris et al. Nov 03, 2025 pp. 4165-4165 10.1182/blood-2025-4165

Abstract Introduction For adults with newly diagnosed B-ALL who achieve complete remission after induction therapy, dete...

The selective JAK1 inhibitor upadacitinib restores impaired neutrophil chemotaxis in the proplatelet formation of immune thrombocytopenia

Qiu-Sha Huang, Qing-Yuan Qu, Zhuo-Yu An et al. Nov 03, 2025 pp. 197-197 10.1182/blood-2025-197

Abstract Introduction Neutrophils are innate immune phagocytes that have a central role in immune defense. Neutrophils have been shown to pl...

TOE1 influences canonical wnt signalling in myeloid leukaemia cells through LEF-1 and regulates the proliferation of haematopoietic cells through PAK2

Hyun Park, Okan Sevim, Megan Wagstaff et al. Nov 03, 2025 pp. 5013-5013 10.1182/blood-2025-5013

Abstract Acute myeloid leukaemia (AML) is an aggressive haematological malignancy characterised by the clonal proliferation of myeloid proge...

Aged B cells as a candidate cell of origin for diffuse large B cell lymphoma: A multi-modal analysis of somatic mutation, clonality, and transcriptional programs

Gal Dadi, Ben Varon, Mohammad Naffaa et al. Nov 03, 2025 pp. 461-461 10.1182/blood-2025-461

Abstract Background: The human B cell repertoire is shaped by V(D)J recombination and somatic hypermutation (SHM) for di...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page